Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Terumo Ties Up with Spenser Technologies of the US in Diagnosis of Cerebral, Cardiac Diseases
August 23, 2004
- Nippon Chemiphar Aims at Reaching 16-17% of Ordinary Profit Ratio to Sales by FY 2008: Mr Yamaguchi
August 23, 2004
- MEDICAL DEVICE NEWS IN BRIEF
August 23, 2004
- 1st Qtr Business Results
August 23, 2004
- BULLETIN
August 23, 2004
- 1st Qtr Business Results
August 23, 2004
- Monkasho Project on Molecular Imaging Techniques to Start from FY2005
August 23, 2004
- Semi-annual Business Results
August 23, 2004
- MONITOR
August 23, 2004
- NEW PRODUCTS
August 23, 2004
- Meet the Leaders (35)
August 23, 2004
- Precautions Revised for 4 Drugs Including Clarithromycin
August 23, 2004
- Daiichi to Return to Track of Growth via Structural Reform
August 23, 2004
- REGULATORY NEWS IN BRIEF
August 23, 2004
- Aiming at Sales of \120 Bil. in 2010: Mr Crenshaw of Eli Lilly Japan
August 23, 2004
- NHO Plans to Improve Domestic Clinical Trials
August 23, 2004
- Eisai to Triple Production of Aricept, Pariet at Kashima Plant
August 23, 2004
- BULLETIN
August 23, 2004
- Mr Komine of MPC Stresses Medicoeconomic Benefits of Zione
August 23, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 23, 2004
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…